Literature DB >> 17178874

Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation.

Ki Y Chung1, Giovanni Morrone, Jan Jacob Schuringa, Magdalena Plasilova, Jae-Hung Shieh, Yue Zhang, Pengbo Zhou, Malcolm A S Moore.   

Abstract

The t(7;11)(p15;p15) translocation, observed in acute myelogenous leukemia and myelodysplastic syndrome, generates a chimeric gene where the 5' portion of the sequence encoding the human nucleoporin NUP98 protein is fused to the 3' region of HOXA9. Here, we show that retroviral-mediated enforced expression of the NUP98-HOXA9 fusion protein in cord blood-derived CD34(+) cells confers a proliferative advantage in both cytokine-stimulated suspension cultures and stromal coculture. This advantage is reflected in the selective expansion of hematopoietic stem cells as measured in vitro by cobblestone area-forming cell assays and in vivo by competitive repopulation of nonobese diabetic/severe combined immunodeficient mice. NUP98-HOXA9 expression inhibited erythroid progenitor differentiation and delayed neutrophil maturation in transduced progenitors but strongly enhanced their serial replating efficiency. Analysis of the transcriptosome of transduced cells revealed up-regulation of several homeobox genes of the A and B cluster as well as of Meis1 and Pim-1 and down-modulation of globin genes and of CAAT/enhancer binding protein alpha. The latter gene, when coexpressed with NUP98-HOXA9, reversed the enhanced proliferation of transduced CD34(+) cells. Unlike HOXA9, the NUP98-HOXA9 fusion was protected from ubiquitination mediated by Cullin-4A and subsequent proteasome-dependent degradation. The resulting protein stabilization may contribute to the leukemogenic activity of the fusion protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178874     DOI: 10.1158/0008-5472.CAN-06-0706

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability.

Authors:  Nayan J Sarma; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  A cancer fate in the hands of a samurai.

Authors:  Malcolm A S Moore
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

3.  Enforced expression of Hoxa5 in haematopoietic stem cells leads to aberrant erythropoiesis in vivo.

Authors:  Dan Yang; Xiangzhong Zhang; Yong Dong; Xiaofei Liu; Tongjie Wang; Xiaoshan Wang; Yang Geng; Shumin Fang; Yi Zheng; Xiaoli Chen; Jiekai Chen; Guangjin Pan; Jinyong Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

4.  Improved ex vivo expansion of adult hematopoietic stem cells by overcoming CUL4-mediated degradation of HOXB4.

Authors:  Jennifer Lee; Jae-Hung Shieh; Jianxuan Zhang; Liren Liu; Yue Zhang; Jae Yong Eom; Giovanni Morrone; Malcolm A S Moore; Pengbo Zhou
Journal:  Blood       Date:  2013-03-21       Impact factor: 22.113

Review 5.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

6.  Near-maximal expansions of hematopoietic stem cells in culture using NUP98-HOX fusions.

Authors:  Hideaki Ohta; Sanja Sekulovic; Silvia Bakovic; Connie J Eaves; Nicolas Pineault; Maura Gasparetto; Clayton Smith; Guy Sauvageau; R Keith Humphries
Journal:  Exp Hematol       Date:  2007-05       Impact factor: 3.084

7.  Nup98-homeodomain fusions interact with endogenous Nup98 during interphase and localize to kinetochores and chromosome arms during mitosis.

Authors:  Songli Xu; Maureen A Powers
Journal:  Mol Biol Cell       Date:  2010-03-17       Impact factor: 4.138

8.  The mobile FG nucleoporin Nup98 is a cofactor for Crm1-dependent protein export.

Authors:  Masahiro Oka; Munehiro Asally; Yoshinari Yasuda; Yutaka Ogawa; Taro Tachibana; Yoshihiro Yoneda
Journal:  Mol Biol Cell       Date:  2010-04-07       Impact factor: 4.138

9.  In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.

Authors:  Anmaar M Abdul-Nabi; Enas R Yassin; Nobish Varghese; Hrishikesh Deshmukh; Nabeel R Yaseen
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

10.  Dissection of the transformation of primary human hematopoietic cells by the oncogene NUP98-HOXA9.

Authors:  Enas R Yassin; Nayan J Sarma; Anmaar M Abdul-Nabi; James Dombrowski; Ye Han; Akiko Takeda; Nabeel R Yaseen
Journal:  PLoS One       Date:  2009-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.